Developing new drugs to fight tuberculosis by targeting protein secretion
Targeting protein secretion in Mycobacterium tuberculosis
This study is looking for new medicines to help treat tuberculosis (TB) by targeting how the bacteria that cause it work, and it will test these potential treatments in mice to see if they can make TB therapy faster and more effective for people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11045778 on NIH RePORTER |
What this research studies
This research focuses on tuberculosis (TB), a significant global health issue, aiming to develop new anti-tubercular drugs that target protein secretion in the bacteria Mycobacterium tuberculosis. The researchers have identified promising molecules through high-throughput screening that can affect both active and dormant bacterial states. By understanding how these molecules inhibit protein synthesis and lead to bacterial cell death, the team hopes to create more effective treatments that can shorten therapy duration. The project will involve testing these drug candidates in mouse models to evaluate their effectiveness against TB.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis, particularly those with drug-resistant strains or those who have difficulty with current treatment regimens.
Not a fit: Patients who do not have tuberculosis or those whose TB is already effectively managed with existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and faster treatments for tuberculosis, potentially saving lives and reducing the burden of this disease.
How similar studies have performed: Previous research has shown promise in targeting bacterial protein secretion as a novel approach to combatting antibiotic resistance, indicating potential for success in this area.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Parish, Tanya — Seattle Children's Hospital
- Study coordinator: Parish, Tanya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.